Document Type
Article
Publication Date
11-27-2020
Publication Title
NPJ Breast Cancer
Abstract
Dynamic contrast-enhanced (DCE) MRI provides both morphological and functional information regarding breast tumor response to neoadjuvant chemotherapy (NAC). The purpose of this retrospective study is to test if prediction models combining multiple MRI features outperform models with single features. Four features were quantitatively calculated in each MRI exam: functional tumor volume, longest diameter, sphericity, and contralateral background parenchymal enhancement. Logistic regression analysis was used to study the relationship between MRI variables and pathologic complete response (pCR). Predictive performance was estimated using the area under the receiver operating characteristic curve (AUC). The full cohort was stratified by hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status (positive or negative). A total of 384 patients (median age: 49 y/o) were included. Results showed analysis with combined features achieved higher AUCs than analysis with any feature alone. AUCs estimated for the combined versus highest AUCs among single features were 0.81 (95% confidence interval [CI]: 0.76, 0.86) versus 0.79 (95% CI: 0.73, 0.85) in the full cohort, 0.83 (95% CI: 0.77, 0.92) versus 0.73 (95% CI: 0.61, 0.84) in HR-positive/HER2-negative, 0.88 (95% CI: 0.79, 0.97) versus 0.78 (95% CI: 0.63, 0.89) in HR-positive/HER2-positive, 0.83 (95% CI not available) versus 0.75 (95% CI: 0.46, 0.81) in HR-negative/HER2-positive, and 0.82 (95% CI: 0.74, 0.91) versus 0.75 (95% CI: 0.64, 0.83) in triple negatives. Multi-feature MRI analysis improved pCR prediction over analysis of any individual feature that we examined. Additionally, the improvements in prediction were more notable when analysis was conducted according to cancer subtype.
Clinical Institute
Women & Children
Clinical Institute
Cancer
Department
Oncology
Recommended Citation
Li, Wen; Newitt, David C; Gibbs, Jessica; Wilmes, Lisa J; Jones, Ella F; Arasu, Vignesh A; Strand, Fredrik; Onishi, Natsuko; Nguyen, Alex Anh-Tu; Kornak, John; Joe, Bonnie N; Price, Elissa R; Ojeda-Fournier, Haydee; Eghtedari, Mohammad; Zamora, Kathryn W; Woodard, Stefanie A; Umphrey, Heidi; Bernreuter, Wanda; Nelson, Michael; Church, An Ly; Bolan, Patrick; Kuritza, Theresa; Ward, Kathleen; Morley, Kevin; Wolverton, Dulcy; Fountain, Kelly; Lopez-Paniagua, Dan; Hardesty, Lara; Brandt, Kathy; McDonald, Elizabeth S; Rosen, Mark; Kontos, Despina; Abe, Hiroyuki; Sheth, Deepa; Crane, Erin P; Dillis, Charlotte; Sheth, Pulin; Hovanessian-Larsen, Linda; Bang, Dae Hee; Porter, Bruce; Oh, Karen Y; Jafarian, Neda; Tudorica, Alina; Niell, Bethany L; Drukteinis, Jennifer; Newell, Mary S; Cohen, Michael A; Giurescu, Marina; Berman, Elise; Lehman, Constance; Partridge, Savannah C; Fitzpatrick, Kimberly A; Borders, Marisa H; Yang, Wei T; Dogan, Basak; Goudreau, Sally; Chenevert, Thomas; Yau, Christina; DeMichele, Angela; Berry, Don; Esserman, Laura J; and Hylton, Nola M, "Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL." (2020). Articles, Abstracts, and Reports. 4146.
https://digitalcommons.providence.org/publications/4146
